Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1959 - Incidence and Survival among Young Women with Stage I-III Breast Cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Alexandra Thomas

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

A. Thomas1, A. Rhoads2, E. Pinkerton2, M.C. Schroeder3, J.J. Oelson2, L.R. McNally4, W.G. Hundley1, K. Conway2, C.F. Lynch2, P.A. Romitti2

Author affiliations

  • 1 Internal Medicine, Wake Forest University, 27157 - Winston Salem/US
  • 2 Public Health, University of Iowa, 52242 - Iowa City/US
  • 3 Pharmacy, University of Iowa, 52242 - Iowa City/US
  • 4 Cancer biology, Wake Forest University, 27157 - Winston Salem/US
More

Resources

Abstract 1959

Background

De novo Stage IV breast cancer (BC) is increasing in premenopausal women. Less is known about current incidence and survival among these women with Stage I-III BC.

Methods

Women ages 20-29 (N = 3,826), 30-39 (N = 34,585), 40-49 (N = 126,552) and 50-59 (N = 172,448) diagnosed with Stage I-III BC from 2000-15 were identified from the US Surveillance, Epidemiology and End Results database. Age-adjusted, annual percentage changes (APC) in incidence and 10-year Kaplan-Meier survival curves were estimated by stage, hormone receptor (HR) status, and grade (low: well/moderately differentiated; high: poorly/undifferentiated) for each age decade.

Results

Stage III BC at presentation decreased with age (20-29 [23.9%], 30-39 [21.9%], 40-49 [16.1%], 50-59 [14.1%]); the opposite pattern was observed for Stage I (23.6%, 28.8%, 42.0%, 48.3%, respectively). HR+ high grade and HR- BCs also decreased with age (20-29 [34.5%, 36.5%], 30-39 [31.1%, 31.6%], 40-49 [23.9%, 21.4%], 50-59 [20.9%, 21.1%]). Among all BC presentations, age-adjusted APC in incidence was higher for women 20-29 (1.6) than those 30-39 (0.3), 40-49 (0.3) or 50-59 (-1.1). Incidence of HR+ low and high-grade BC increased for women <50 with the highest APC (5.7 and 3.8, respectively) for women 20-29; HR- BC incidence decreased for all ages. Among women 20-29, 10-year survival was lowest for those with HR+ high grade BC (Table); for this group, the greatest survival difference between HR+ high grade and HR- BC was for Stage I BC (79.8% vs 89.3%) compared to Stage II (77.2% vs 80.7%) or Stage III (44.9% vs 45.0%). Comparing Stage III BC across age decades, 10-year survival was lowest for women 20-29, notably for HR+ BC.Table: 245P

StageHR StatusGrade10-Year Survival % (Standard Error)
Age (years)
20-2930-3940-4950-59
Any+Low81.2 (1.9)85.4 (0.5)91.1 (0.2)89.2 (0.1)
+High67.7 (2.0)75.3 (0.6)80.2 (0.3)77.1 (0.3)
-73.8 (1.5)74.3 (0.5)75.1 (0.3)74.3 (0.3)
Stage III+Low54.2 (5.7)62.8 (1.6)73.7 (0.7)68.3 (0.7)
+High44.9 (3.9)55.7 (1.3)60.1 (0.8)54.2 (0.8)
-45.0 (3.5)49.2 (1.2)49.8 (0.8)47.5 (0.7)

Conclusions

Among young women, HR+ BC is increasing in incidence and associated with reduced survival for those 20-29. Understanding the etiologies underlying these trends may inform strategies directed toward improving outcomes for these women.

Clinical trial identification

Legal entity responsible for the study

University of Iowa.

Funding

United States Centers for Disease Control and Prevention (U01DD001035) and the Nealie Belk Stevens Fund for Breast Cancer Research.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings